PIK3CA and glioblastoma: The combination of sonidegib and buparlisib (BKM120, [211,212]), a pan-PI3K antagonist, inhibited PTEN-deficient glioblastoma growth in neurosphere culture assays and in vivo, whereas the drugs as single agents had little effect [195].